Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by coalbeton Dec 17, 2019 11:42am
147 Views
Post# 30463816

China even has worse stats!

China even has worse stats!

Bladder cancer: a cancer in crisis - InSight+ 20, 27 May 2019

https://insightplus.mja.com.au/2019/20/bladder-cancer-a-cancer-in-crisis

2019-05-27 · Despite a falling age-standardised incidence of bladder cancer from 17.8 per 100 000 in 1982 to a projected 10.1 per 100 000 in 2019, mortality–incidence ratio has increased from 0.28 to 0.38 over the past two decades. Unfortunately, many Australian health care practitioners remain unaware of this bladder cancer survival crisis.


Bullboard Posts